=
Note: Conversion is based on the latest values and formulas.
Machine Learning in Medicine | NEJM - New England Journal of … 3 Apr 2019 · In this view of the future of medicine, patient–provider interactions are informed and supported by massive amounts of data from interactions with similar patients. These data are …
Lepodisiran - The New England Journal of Medicine 30 Mar 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small …
AI in Medicine | NEJM 29 Mar 2023 · AI in Medicine explores the history and vast potential of artificial intelligence and machine learning across all areas of health care.
Nerandomilast in Patients with Progressive Pulmonary Fibrosis 19 May 2025 · Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has …
First-Line Camizestrant for Emerging - The New England Journal … 1 Jun 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) …
Once-Monthly Maridebart Cafraglutide for the Treatment of … 23 Jun 2025 · Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent …
The New England Journal of Medicine | Research & Review … The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Nonoperative Management of Mismatch Repair–Deficient Tumors 27 Apr 2025 · Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion …
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple … 8 Apr 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying …
Tirzepatide as Compared with Semaglutide for the Treatment of … 11 May 2025 · Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults …